AI Engines For more Details: Perplexity Kagi Labs You
Mitochondrial Poisoning: Antimycin A works by inhibiting the function of complex III (cytochrome bc1 complex) in the mitochondrial electron transport chain. This inhibition disrupts the normal flow of electrons and interferes with oxidative phosphorylation, the process by which cells generate ATP (adenosine triphosphate) for energy. As a result, cells are unable to produce energy efficiently, leading to metabolic dysfunction and cell death.
Research Tool: Despite its toxic effects, antimycin A is widely used as a research tool in cell biology, biochemistry, and pharmacology. It is commonly employed to study mitochondrial function, electron transport chain activity, and cellular responses to oxidative stress.
Antibiotic Activity: Antimycin A possesses antibiotic properties and is capable of inhibiting the growth of certain bacteria and fungi. Its mechanism of action involves disrupting the synthesis of ATP in microbial cells, leading to cellular dysfunction and death.
Toxicity: Antimycin A is highly toxic to cells and organisms due to its ability to disrupt mitochondrial function. In addition to inhibiting ATP synthesis, it can also induce the production of reactive oxygen species (ROS) and trigger apoptosis (programmed cell death). These toxic effects make antimycin A unsuitable for use as a therapeutic agent in humans.
Environmental Impact: Antimycin A is also used in agriculture as a piscicide (fish poison) to control unwanted fish populations in aquaculture facilities and natural water bodies. Its application as a pesticide raises environmental concerns due to its potential toxicity to non-target organisms and ecosystem disruption.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 1.6 | 1.6 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 2.1 | 1.5 | 0.4 |
| Allergies | 2.4 | 0.8 | 2 |
| Allergy to milk products | 1 | 1.6 | -0.6 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 2.3 | 3.1 | -0.35 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.2 | 3.5 |
| Ankylosing spondylitis | 2.3 | 0.3 | 6.67 |
| Anorexia Nervosa | 1.2 | 1.1 | 0.09 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 1.9 | 0.9 | 1.11 |
| Atherosclerosis | 1.1 | 0.2 | 4.5 |
| Atrial fibrillation | 1.6 | 2.2 | -0.38 |
| Autism | 3.9 | 3.4 | 0.15 |
| Autoimmune Disease | 1.2 | 0.5 | 1.4 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1.5 | 1.5 | |
| Brain Trauma | 0.9 | 0.6 | 0.5 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 1.7 | -1.7 | |
| Carcinoma | 2.2 | 1.3 | 0.69 |
| Celiac Disease | 0.8 | 1.1 | -0.38 |
| Cerebral Palsy | 1.1 | 0.3 | 2.67 |
| Chronic Fatigue Syndrome | 1.6 | 1.9 | -0.19 |
| Chronic Kidney Disease | 2.5 | 1.4 | 0.79 |
| Chronic Lyme | 0.3 | 0.3 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 0.3 | 4.33 |
| Chronic Urticaria (Hives) | 1.3 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.3 | 4 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 3.7 | 1.6 | 1.31 |
| Constipation | 0.9 | 0.9 | |
| Coronary artery disease | 1.7 | 0.9 | 0.89 |
| COVID-19 | 3.6 | 3.4 | 0.06 |
| Crohn's Disease | 3.2 | 1.9 | 0.68 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 0.6 | 0.33 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 0.9 | 0.6 | 0.5 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 4.5 | 4.3 | 0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.1 | 1.3 | -0.18 |
| Endometriosis | 2.1 | 0.2 | 9.5 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.6 | 1.2 | 1.17 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 1.6 | 1 | 0.6 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 1.8 | 0.39 |
| gallstone disease (gsd) | 1.5 | 0.3 | 4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0.3 | 0 |
| Generalized anxiety disorder | 1.5 | 1.2 | 0.25 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.2 | 2 |
| Graves' disease | 1.3 | 1.2 | 0.08 |
| Gulf War Syndrome | 0.5 | 0.3 | 0.67 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.2 | 1.1 | 0.09 |
| Heart Failure | 2.4 | 0.9 | 1.67 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 1 | 0.3 | 2.33 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
| hyperglycemia | 1.3 | 1 | 0.3 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.9 | 1 | 1.9 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 1 | 0.8 | 0.25 |
| Inflammatory Bowel Disease | 4.6 | 2.8 | 0.64 |
| Insomnia | 1.1 | 0.9 | 0.22 |
| Intelligence | 0.9 | 0.9 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 2.8 | 2 | 0.4 |
| ischemic stroke | 1.6 | 1.2 | 0.33 |
| Liver Cirrhosis | 3.1 | 1.3 | 1.38 |
| Long COVID | 3.1 | 1.9 | 0.63 |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.5 | 0.6 | -0.2 |
| ME/CFS without IBS | 0.5 | 0.9 | -0.8 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 2.9 | 2.2 | 0.32 |
| Mood Disorders | 4.8 | 4.3 | 0.12 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
| Multiple Sclerosis | 3.8 | 3 | 0.27 |
| Multiple system atrophy (MSA) | 0.6 | 0.3 | 1 |
| myasthenia gravis | 0.9 | 0.2 | 3.5 |
| neuropathic pain | 1.1 | -1.1 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 1.3 | 0.85 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.6 | 0.5 |
| Obesity | 3.8 | 3.5 | 0.09 |
| obsessive-compulsive disorder | 2.4 | 1.8 | 0.33 |
| Osteoarthritis | 2.2 | 0.9 | 1.44 |
| Osteoporosis | 1.1 | 0.6 | 0.83 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 4.2 | 3.6 | 0.17 |
| Polycystic ovary syndrome | 2.7 | 1.1 | 1.45 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.3 | 1 | -2.33 |
| Primary sclerosing cholangitis | 1.8 | 1 | 0.8 |
| Psoriasis | 1.2 | 1.6 | -0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.7 | 0.47 |
| Rosacea | 0.8 | 0.2 | 3 |
| Schizophrenia | 2.7 | 1.2 | 1.25 |
| scoliosis | 0.2 | 0.2 | |
| Sjögren syndrome | 1.3 | 1.5 | -0.15 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.3 | 0.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 0.1 | 9 |
| Stress / posttraumatic stress disorder | 1.4 | 1.3 | 0.08 |
| Systemic Lupus Erythematosus | 1.9 | 0.8 | 1.37 |
| Tic Disorder | 0.3 | 0.6 | -1 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.4 | 1.5 | -0.07 |
| Type 2 Diabetes | 3 | 2.4 | 0.25 |
| Ulcerative colitis | 3.5 | 1.8 | 0.94 |
| Unhealthy Ageing | 1.5 | 1.3 | 0.15 |
| Vitiligo | 1.3 | 0.9 | 0.44 |
